BAKER BROS. ADVISORS LP's Net Worth

$1.73 Billion

Who is BAKER BROS. ADVISORS LP?

BAKER BROS. ADVISORS LP has an estimated net worth of $1.73 Billion. This is based on reported shares across multiple companies, which include Seagen Inc., RHYTHM PHARMACEUTICALS, INC., BeiGene, Ltd., INCYTE CORP, Invitae Corp, Prelude Therapeutics Inc, XOMA Corp, Kiniksa Pharmaceuticals, Ltd., Mirati Therapeutics, Inc., Zymeworks Inc., Intellia Therapeutics, Inc., Entrada Therapeutics, Inc., IGM Biosciences, Inc., Kodiak Sciences Inc., ACADIA PHARMACEUTICALS INC, BIOCRYST PHARMACEUTICALS INC, IDERA PHARMACEUTICALS, INC., DBV Technologies S.A., TScan Therapeutics, Inc., Neoleukin Therapeutics, Inc., Atreca, Inc., Aeglea BioTherapeutics, Inc., BELLICUM PHARMACEUTICALS, INC, HOOKIPA Pharma Inc., Talis Biomedical Corp, ALEXION PHARMACEUTICALS, INC., MADRIGAL PHARMACEUTICALS, INC., SYNAGEVA BIOPHARMA CORP, GENOMIC HEALTH INC, Principia Biopharma Inc., and Ardea Biosciences, Inc./DE.

SEC CIK

BAKER BROS. ADVISORS LP's CIK is 0001263508

Past Insider Trading and Trends

2016 was BAKER BROS. ADVISORS LP's most active year for acquiring shares with 455 total transactions. BAKER BROS. ADVISORS LP's most active month to acquire stocks was the month of April. 2019 was BAKER BROS. ADVISORS LP's most active year for disposing of shares, totalling 379 transactions. BAKER BROS. ADVISORS LP's most active month to dispose stocks was the month of October. 2013 saw BAKER BROS. ADVISORS LP paying a total of $53,806,389,065.11 for 550,400,647 shares, this is the most they've acquired in one year. In 2013 BAKER BROS. ADVISORS LP cashed out on 117,349,500 shares for a total of $49,999,570,365.60, their largest year based on trade value.